Hadassah

Oral Insulin Pill, Based on Hadassah Medical Center Research, Cleared by FDA for Clinical Trial in US

Tuesday, May 21 2013

The oral insulin pill (ORMD-0801), based on over 30 years of research by Hadassah Medical Center scientists, and developed by the Israeli company, Oramed Pharmaceuticals Inc., has been cleared by the United States Food and Drug Administration (FDA) for Phase 2 clinical trials in the US.

The orally ingestible capsule is indicated for those with early stage type two diabetes, when it can slow the rate of disease progression by providing additional insulin to the body and allowing the pancreas a respite. The pill delivery system has the advantage of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, Chief Executive Officer of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

Read more about the insulin pill from Hadassah International>>

Related Stories

alt_text

Tuesday, Jul 14 2020

Hadassah and Mexican Mental Health Experts Address COVID-19 Anxiety

Under the auspices of Hadassah International, two mental health specialists from opposite ends of the world joined together for a July 5 webinar...

READ MORE ›
alt_text

Tuesday, Jul 14 2020

Hadassah and Argentinian Mental Health Experts Address COVID-19 Anxiety

As part of a global mission to share its successful COVID-19 hospital protocols, the Hadassah Medical Organization, together with Hadassah International, presented HMO’s Manual of Protocols...

READ MORE ›
alt_text

Wednesday, Jul 8 2020

Cancer Trailblazers at Hadassah Prioritize a Spirit of Innovation

For many decades, chemotherapy and radiation were the chief therapies to treat cancer. Today, at major medical centers like the Hadassah Medical Organization, cancer specialists...

READ MORE ›
alt_text

Monday, Jul 6 2020

Evolution, Findings, and Outlook—Hadassah Director Reflects on COVID-19

Many people around the world watched with admiration as Israel efficaciously contained COVID-19 at the start of the pandemic with a strict lockdown...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More